An open-label, single-dose, parallel group study to evaluate the effects of age and gender on the pharmacokinetics, safety, and tolerability of HCV-796 administered orally to healthy subjects
Phase of Trial: Phase I
Latest Information Update: 16 Apr 2008
At a glance
- Drugs Nesbuvir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Wyeth
- 16 Apr 2008 Development of nesbuvir has been discontinued due to safety issues, according to a ViroPharma media release.
- 11 Apr 2008 Status changed from recruiting to completed.
- 12 Dec 2006 New trial record.